Can we safely reduce the administration of 131-iodine in patients with differentiated thyroid cancer? – experience of the Brugmann hospital in Brussels

Can we safely reduce the administration of 131-iodine in patients with differentiated thyroid cancer? – experience of the Brugmann hospital in Brussels

Abstract Background 131-iodine (131I) administration after surgery remains a standard practice in differentiated thyroid cancer (DTC). In 2014, the American Thyroid Association presented new guidelines for the staging and management of DTC, including no systematic 131I in patients at low-risk of rec...

Full description

Bibliographic Details
Main Authors: Laura Iconaru, Felicia Baleanu, Georgiana Taujan, Ruth Duttmann, Linda Spinato, Rafik Karmali, Pierre Bergmann, Anne-Sophie Hambye
Format: Article
Language:English
Published: BMC 2020-09-01
Series:Thyroid Research
Subjects:
Differentiated thyroid cancer
131-iodine therapy
Therapeutic response
Online Access:http://link.springer.com/article/10.1186/s13044-020-00089-4

Internet

http://link.springer.com/article/10.1186/s13044-020-00089-4

Similar Items